fbpx

Weekly Top News – Breast Cancer – January 27, 2020

January 27, 2020

Talzenna (talazoparib) / Pfizer
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) – Jan 24, 2020 – P3; N=429; Recruiting; Sponsor: BioMarin Pharmaceutical

 

Kadcyla (ado-trastuzumab emtansine) / Roche
Swiss Regulator grants additional approval for Roche’s antibody-drug Kadcyla (Reuters) – Jan 24, 2020 – “ROCHE’S KADCYLA APPROVED FOR A NEW INDICATION IN EARLY HER2-POSITIVE BREAST CANCER IN SWITZERLAND…ADDITIONAL APPROVAL OF KADCYLA IS BASED ON THE PHASE III KATHERINE STUDY, IN WHICH PATIENTS WITH AN EARLY FORM OF HER2-POSITIVE BREAST CANCER WHO WERE TREATED WITH KADCYLA HAD A 50% REDUCED RISK OF RELAPSE OR DEATH COMPARED TO STANDARD THERAPY.”

 

Tecentriq (atezolizumab) / Roche
IMpassion131: A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) – Jan 22, 2020 – P3; N=600; Recruiting; Sponsor: Hoffmann-La Roche; Active, not recruiting –> Recruiting

 

Ibrance (palbociclib) / Pfizer
Ibrance pricing: Wholesale acquisition cost of $10,963/month (Cowen & Co) – Jan 24, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 646; REPORT TITLE: – “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

 

Kisqali (ribociclib) / Novartis
Kisqali pricing: $10,950/600mg for 28-days, $8,760/400mg dose and $4,380/200mg dose (Cowen & Co) – Jan 24, 2020 – A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 548; REPORT TITLE: – “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020

No Comments

Post a Comment

Comment
Name
Email
Website